difelikefalin治疗血液透析相关皮肤瘙痒的研究进展  

Progress of Difelikefalin in the Treatment of Hemodialysis Pruritus

作　　者：韩清霞 杜静[2] 赵战云[2] HAN Qingxia;DU Jing;ZHAO Zhanyun(Weifang Second Medical University,Weifang 261000,China;Nephrology Medical Center,Weifang People’s Hospital,Weifang 261000,China)

机构地区：[1]山东第二医科大学,山东潍坊261000 [2]潍坊市人民医院肾脏病医学中心,山东潍坊261000

出　　处：《药物生物技术》2024年第4期454-456,共3页Pharmaceutical Biotechnology

摘　　要：血液透析患者的常见并发症之一即皮肤瘙痒,不仅影响患者的身心健康、增加死亡风险,也为患者家庭、医护人员及社会带来了巨大负担。瘙痒的发病机制有多种假说存在,但目前仍未有定论,针对该并发症的治疗也缺少针对性策略。文章主要就FDA新近批准药物difelikefalin治疗血液透析相关皮肤瘙痒的生理机制、治疗进展等作一综述。One of the common complications of hemodialysis patients was pruritus,not only affected the physical and mental health of the patients and increased the risk of mortality,but also imposed a significant burden on patients’families,healthcare providers,and society.Various hypotheses regarding the pathogenesis of pruritus existed,but the jury was still out.There was also a lack of targeted strategies for the treatment of this complication.The physiological mechanism and progress of difelikefalinof FDA recently approved the drug in the treatment of hemodialysis-related pruritus were reviewed in this article.

关 键 词：慢性肾脏病相关性瘙痒症 地非法林 肾透析 药物治疗 

分 类 号：R692[医药卫生—泌尿科学]